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ABSTRACT
Motivation: The Affymetrix Human Exon Junction Array is a newly
designed high-density exon-sensitive microarray for global analysis
of alternative splicing. Contrary to the Affymetrix exon 1.0 array,
which only contains four probes per exon and no probes for exon–
exon junctions, this new junction array averages eight probes per
probeset targeting all exons and exon–exon junctions observed
in the human mRNA/EST transcripts, representing a signiﬁcant
increase in the probe density for alternative splicing events. Here,
we present MADS+, a computational pipeline to detect differential
splicing events from the Affymetrix exon junction array data. For each
alternative splicing event, MADS+ evaluates the signals of probes
targeting competing transcript isoforms to identify exons or splice
sites with different levels of transcript inclusion between two sample
groups. MADS+ is used routinely in our analysis of Affymetrix exon
junction arrays and has a high accuracy in detecting differential
splicing events. For example, in a study of the novel epithelial-
speciﬁc splicing regulator ESRP1, MADS+ detects hundreds of
exons whose inclusion levels are dependent on ESRP1, with a
RT-PCR validation rate of 88.5% (153 validated out of 173 tested).
Availability: MADS+ scripts, documentations and annotation
ﬁles are available at http://www.medicine.uiowa.edu/Labs/Xing/
MADSplus/.
Contact: yi-xing@uiowa.edu
1 INTRODUCTION
Alternative splicing of precursor mRNAs is a prevalent regulatory
mechanism in higher eukaryotes. Recent data suggest that over 90%
of multi-exon human genes are alternatively spliced (Blencowe
et al., 2009). Use of splicing-sensitive microarrays is a popular
approach for global proﬁling of alternative splicing events. One
widely used commercial platform is the Affymetrix exon 1.0 array
(Clark et al., 2007). This array allocates on average four probes
per exon for all transcript-conﬁrmed and predicted exons in a
mammalian genome, allowing for concurrent proﬁling of gene
expression levels and alternative splicing events. Since its release, a
variety of algorithms for splicing analysis using the exon 1.0 array
havebeenproposed[forasummaryofthesealgorithms,see(Laajala
et al., 2009)].
∗To whom correspondence should be addressed.
However, as a ﬁrst-generation exon array platform, the design of
the Affymetrix exon 1.0 array has its limitations. Most importantly,
the array has only four probes per exon and no probes targeting
exon–exon junctions. To address these limitations, Affymetrix
recently released its second-generation exon array, the Human Exon
JunctionArray (HJAY), with a signiﬁcantly improved probe design.
This new array averages eight probes per probeset for 315137
exons and 260488 exon–exon junctions in the human genome,
covering all alternative splicing events with mRNA/EST evidence
in the UCSC/Ensembl databases (Yamamoto et al., 2009). The
increasedprobedensity,inclusionofexon–exonjunctionprobesand
comprehensive coverage of known alternative splicing events make
the HJAY a powerful platform for analysis of alternative splicing.
Building on our previous work on the exon 1.0 array (Xing et al.,
2008), we have developed a pipeline, MADS+, for splicing analysis
using the new Affymetrix exon junction array.
2 DESCRIPTIONS
MADS+ is implemented in Python/R and can be run on any
Linux/Unix-like environment with installation of Python, R and
required packages.An overview of the MADS+ pipeline is provided
below:
Preprocessing: raw junction array CEL ﬁles are processed by
the ProbeEffects program (Kapur et al., 2007). A variety of
background-correction and normalization methods are implemented
in ProbeEffects. In particular, we employ a linear model with 80
parameters to correct for the background intensities of individual
probes based on nucleotides at each position of a 25mer probe
(Kapur et al., 2007). The background-corrected intensities are used
for downstream analysis.
Expression Index Calculation: for each gene, the background
corrected and normalized intensities of its exon probes are used to
derive an index for overall gene expression levels. The ProbeSelect
programimplementsaniterativeprobeselectionalgorithmtoselecta
subsetofexonprobesforeachgenewithhighlycorrelatedintensities
across all samples (Xing et al., 2006). These probes are treated as
reliable indicators of overall gene expression levels and their probe
intensities are ﬁtted to the Li-Wong model to calculate expression
indexes (Li et al., 2001; Xing et al., 2006).
Alternative Splicing Analysis: the alternative splicing analysis in
MADS+ consists of several steps. First, for each probe in a
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Fig. 1. Detection of a differentially spliced cassette exon using MADS+.
(A) The HJAY probe design for cassette exons. Each probeset has eight
probes. (B) Exon 13 of SLK is positively regulated by ESRP1. (C) The
HJAY data indicate signiﬁcantly elevated exon inclusion of SLK exon 13
in response to ESRP1 overexpression. In each panel, the dashed red line
indicates the average gene expression levels of SLK in four replicate samples
transduced with EVor ESRP1.The individual blue lines indicate the average
background-corrected intensities of individual probes in a probeset. MADS+
P-value is shown below the name of each probeset. The ‘+’ and ‘−’ signs
indicate the direction of change in splicing indexes from EV to ESRP1.
particular sample, we calculate a ‘splicing index’, represented as
the background corrected probe intensity divided by the estimated
gene expression index.Two separate one-sided t-tests are performed
to test if the splicing index of a probe is substantially higher in
one sample group over the other group. Then, for each probeset,
the P-values of individual probes are summarized using Fisher’s
method to obtain a probeset-level P-value for differential splicing
(Xing et al., 2008). Next, MADS+ reads precompiled annotation
ﬁlesofalternativesplicingeventsqueriedbytheexonjunctionarray.
For each alternative splicing event, MADS+ evaluates the P-values
of multiple probesets targeting exons and exon–exon junctions,
requiringoppositetrendsforprobesetstargetingcompetingisoforms
as evidence of differential splicing. For example, for each exon
skipping event, we require that the ‘skip’ probeset and at least
one of the three ‘include’ probesets (see Fig. 1A) have P-values
below a predeﬁned signiﬁcance cutoff (default is 0.001), and that
signiﬁcant ‘include’and ‘skip’probesets display opposite directions
of change in splicing index between the two sample groups.
Finally, for candidate differential splicing events, MADS+ plots
the background-corrected intensities of individual probes as well
as the estimated gene expression indexes, allowing users to directly
inspect the evidence for splicing differences between sample groups
(see Fig. 1C for an example). It also produces annotated text output
grouped according to the types of alternative splicing patterns (e.g.
exon skipping, alternative splice site usage, mutually exclusive
exon usage). This facilitates downstream analysis of identiﬁed
differential splicing events.
3 EXAMPLES
The MADS+ pipeline has been used routinely in our exon-level
analysis of the Affymetrix HJAY data. Figure 1 shows a candidate
differential exon skipping event identiﬁed by MADS+. In this study,
in order to identify splicing events regulated by the novel epithelial-
speciﬁc splicing regulator ESRP1 (Warzecha et al., 2009), a cDNA
for mouse ESRP1 was ectopically expressed in the MDA-MB-231
mesenchymal human breast cancer cell line by viral transduction
compared with empty vector (EV) control and proﬁled by the
Affymetrix HJAY (four biological replicates each condition). As
showninFigure1,exon13oftheSLK genewaspositivelyregulated
by ESRP1. Its exon inclusion level was 2% after transduction by EV
and 80% after transduction by ESRP1. From the HJAY data of this
exon, we found signiﬁcantly elevated splicing indexes of the exon
inclusion probesets (upstream junction, downstream junction and
exon)andsigniﬁcantlyreducedsplicingindexesoftheexonskipping
probeset in the ESRP1 group as compared with the EV group (Fig.
1C), which was validated by RT-PCR (Fig. 1B). In sum, among
ESRP1-dependent exon skipping events identiﬁed by MADS+, we
obtained a RT-PCR validation rate of 88.5% (153 exons validated
out of 173 tested so far, Warzecha,C.C. et al., unpublished data).
This example demonstrates that MADS+ is a useful tool for global
analysis and visualization of differential alternative splicing.
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